Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04024891 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis
A Phase 2 study, sponsored by Ocuphire Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT04024891 is a Phase 2 study that has completed, run by Ocuphire Pharma. The registered enrollment target is 32 participants.
The verdict
NCT04024891, a Phase 2 study, has completed, sponsored by Ocuphire Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objectives of this study are: * To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis * To evaluate the safety of Nyxol * To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially associated with administration of Nyxol
Interventions
- OTHER Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- DRUG Phentolamine Mesylate Ophthalmic Solution 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04024891
The ClinicalTrials.gov registry entry for NCT04024891 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocuphire Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) is the first listed.
NCT04024891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04024891 about?
NCT04024891 is a clinical study titled "Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis". The objectives of this study are: * To evaluate the efficacy of Nyxol (phentolamine mesylate ophthalmic solution 1%) to expedite the reversal of pharmacologic mydriasis * To evaluate the safety of Nyxol * To evaluate the effect of Lumify® to suppress conjunctival hyperemia (redness) potentially ass...
What is the current status of trial NCT04024891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-08-13. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT04024891?
The interventions under investigation include: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) (OTHER), Phentolamine Mesylate Ophthalmic Solution 1% (DRUG).
Who is sponsoring clinical trial NCT04024891?
This trial is sponsored by Ocuphire Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.